These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 16226710)

  • 21. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signal transduction by several KIT juxtamembrane domain mutations.
    Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
    Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new twist in the transmembrane signaling tool-kit.
    Lemmon MA; Ferguson KM
    Cell; 2007 Jul; 130(2):213-5. PubMed ID: 17662934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor.
    Thömmes K; Lennartsson J; Carlberg M; Rönnstrand L
    Biochem J; 1999 Jul; 341 ( Pt 1)(Pt 1):211-6. PubMed ID: 10377264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.
    Reber L; Da Silva CA; Frossard N
    Eur J Pharmacol; 2006 Mar; 533(1-3):327-40. PubMed ID: 16483568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction and functional cooperation between the serine/threonine kinase bone morphogenetic protein type II receptor with the tyrosine kinase stem cell factor receptor.
    Hassel S; Yakymovych M; Hellman U; Rönnstrand L; Knaus P; Souchelnytskyi S
    J Cell Physiol; 2006 Feb; 206(2):457-67. PubMed ID: 16155937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
    Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
    Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain.
    Walter M; Lucet IS; Patel O; Broughton SE; Bamert R; Williams NK; Fantino E; Wilks AF; Rossjohn J
    J Mol Biol; 2007 Mar; 367(3):839-47. PubMed ID: 17292918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
    Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
    Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain.
    Jahn T; Seipel P; Coutinho S; Urschel S; Schwarz K; Miething C; Serve H; Peschel C; Duyster J
    Oncogene; 2002 Jul; 21(29):4508-20. PubMed ID: 12085229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
    Mol CD; Fabbro D; Hosfield DJ
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages.
    Kimura Y; Jones N; Klüppel M; Hirashima M; Tachibana K; Cohn JB; Wrana JL; Pawson T; Bernstein A
    Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6015-20. PubMed ID: 15067126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.
    Isozaki K; Terris B; Belghiti J; Schiffmann S; Hirota S; Vanderwinden JM
    Am J Pathol; 2000 Nov; 157(5):1581-5. PubMed ID: 11073817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.